Clinical rigor is what turns Omada from “another vendor” into infrastructure for cardiometabolic care. OmadaSpark — an AI-powered tool built with Llama models on Amazon SageMaker AI — doesn’t replace care teams; it amplifies them, delivering evidence-based nutrition education and motivational interviewing between visits. Members who use OmadaSpark are 3x more likely to return to the app. Learn how we built it with AWS AI and AI at Meta: https://lnkd.in/di4uSZr6
The GLP-1 landscape just changed again. The FDA recently approved Eli Lilly and Company's Foundayo™ (orforglipron), joining Novo Nordisk's oral Wegovy® as the newest oral options in a rapidly expanding category. In our latest edition of Proof Points, Endocrinologist and Obesity Medicine Specialist, Rajiv R. breaks down the clinical differences between oral and injectable GLP-1s and how the growing range of options is re-shaping obesity care. Read it here ↓
Thank you to Northeast Business Group on Health for inviting us to be a sponsor at: Cardiometabolic Health as a Business Imperative Conference and featuring our CMO Thomas Tsang, MD, MPH to speak. Dr. Tsang took part in a timely panel discussion (Breaking Down the Silos: Heart, Obesity & Diabetes) with other leading industry figures, including Emmanuelle Clerisme-Beaty, MD and Cara Pensabene, MD. Dr. Tsang’s participation on this panel was noteworthy, as Omada’s perspective on population-level virtual care solutions for heart health, obesity and diabetes is unique in the market. With the recent addition of Omada for Cholesterol, Omada’s suite of program offerings now covers all three chronic conditions spotlighted during the panel discussion. We value these exciting opportunities to represent Omada during important conversations about how benefits leaders are shaping the future of healthcare. See you at the next conference!
The latest Omada platform expansion is here: GLP-1 guided medication care. We’re adding GLP-1 prescribing to our proven behavior change platform, helping members experience not only the strong start these medications can provide, but a prescription that works hand in hand with an entire ecosystem of care. That ecosystem already features a dedicated health coach, education, digital tools and tailored support that can include cardiometabolic specialists, an exercise specialist and more. Our GLP-1 guided medication care expands this by including prescribing and medication management from licensed providers trained in obesity treatment. Read more: https://buff.ly/dMBVG3c
Behavior change doesn’t happen in a single visit — and it rarely happens in a straight line. Here’s what adaptive care looks like in everyday life: adjusting goals as circumstances change, using technology to make food choices easier, and turning data into actionable insights. This is compassionate intelligence in action: human coaching, powered by insights, to bend the curve of chronic disease Learn more: https://lnkd.in/d6qDdGwb
We’ve expanded Omada’s cardiometabolic platform with Omada for Cholesterol, so one program can support obesity, diabetes, hypertension, cholesterol, and GLP‑1 use. Omada for Cholesterol provides members with: 💡Tailored cholesterol support and goal‑setting from a dedicated care team cardiometabolic specialists 💡 A heart‑healthy community for accountability and momentum 💡Integrated behavior change tools and medication adherence support For employers and health plans, that means a single, integrated partner for highly prevalent conditions — and a strategy that reflects how cardiovascular risk really accumulates, across multiple comorbidities over time. Learn more: https://lnkd.in/eqjgs-ir
GLP-1s are dramatically changing obesity treatment. But how can we help optimize the investment — for employers and for the people who need them? Omada’s answer: GLP-1 guided medication care. We’re expanding our platform to include GLP-1 prescribing, so from the very start of a GLP-1 prescription, our members have a continuous, tailored experience that includes prescriber, coach, and behavioral and lifestyle support guiding the way. The goal: make every prescription an investment in company and workforce health. Learn more: https://lnkd.in/dWivJ4yT
Human care. Smart technology. One integrated platform. What’s our latest addition? At Omada, we care for members with multiple chronic conditions, and now that includes high cholesterol. Chronic disease doesn’t travel alone and we believe that the best health care delivery model is a holistic one where all facets of a member’s life, including comorbidities, are incorporated into the care plan. That’s what’s behind Omada for Cholesterol. 86 million Americans are living with cholesterol levels that increase cardiovascular risk. Through innovation, impact, and whole-person care, we’re here to help change that. Together. Learn more about our research and innovation process: https://buff.ly/31nWb37
❓True or false? While taking a GLP-1, all that matters is seeing the number on the scale go down. ❌False! It begs the question: who is – and isn’t – being set up for long-term weight loss success? Many people may not even be aware of the GLP-1 side effect of losing lean mass caused by rapid weight loss. In fact, resistance training staying strong–or even getting stronger–and boosting metabolism while taking a GLP-1 can help preserve lean mass while maintaining a healthy weight for the long haul. Learn more, including what Omada is doing to help GLP-1 members preserve muscle mass in our recent whitepaper. https://buff.ly/KbBmwNv
Omada’s Chief Medical Officer, Thomas Tsang, MD, MPH recently spoke with Fierce Healthcare about why high cholesterol can’t be treated as an afterthought in cardiometabolic care. With up to 70% of adults with obesity also living with high cholesterol, many still never reach healthy LDL levels, likely because support is episodic. Our new offering, Omada for Cholesterol, is designed to meet members where they’re at with between‑visit support and human‑led coaching amplified by AI, all in the same integrated platform that supports obesity, hypertension, diabetes, and GLP-1s. Read the full story: https://buff.ly/Fkxj4Ry
